Huperzine A (Herb/Suppl)

Brand and Other Names:Chinese club moss, Huperzine Rx-Brain, more...HUP, HUP A, Memorall, selagine
  • Print

Suggested Dosing

Alzheimer Disease & Multi-infarct Dementia

50-200 mcg PO BID

Senile or presenile dementia

30 mcg PO BID

Prevention of muscle weakness in myasthenia gravis

400 mcg IM qDay

Next:

Suggested Uses

Improve memory; treatment of Alzheimer's disease, protection from neurotoxic agents including organophosphate nerve gases, glutamate toxicity, and treating myasthenia gravis

Efficacy

Clinical studies in progress; preliminary results promising

Previous
Next:

Interactions

Interaction Checker

and Huperzine A

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (66)

                • aclidinium

                  huperzine A increases and aclidinium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • amitriptyline

                  huperzine A increases and amitriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • amoxapine

                  huperzine A increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • anticholinergic/sedative combos

                  huperzine A increases and anticholinergic/sedative combos decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • atracurium

                  huperzine A increases and atracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • atropine

                  huperzine A increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • atropine IV/IM

                  huperzine A increases and atropine IV/IM decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

                • belladonna alkaloids

                  huperzine A increases and belladonna alkaloids decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • belladonna and opium

                  huperzine A increases and belladonna and opium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • bethanechol

                  bethanechol and huperzine A both increase cholinergic effects/transmission. Use Caution/Monitor.

                • carbachol

                  carbachol and huperzine A both increase cholinergic effects/transmission. Use Caution/Monitor.

                • cevimeline

                  cevimeline and huperzine A both increase cholinergic effects/transmission. Use Caution/Monitor.

                • cisatracurium

                  huperzine A increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • clomipramine

                  huperzine A increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • cyclizine

                  huperzine A increases and cyclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • cyclobenzaprine

                  huperzine A increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • darifenacin

                  huperzine A increases and darifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • desipramine

                  huperzine A increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • dicyclomine

                  huperzine A increases and dicyclomine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • diphenhydramine

                  huperzine A increases and diphenhydramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • donepezil

                  donepezil and huperzine A both increase cholinergic effects/transmission. Use Caution/Monitor.

                • dosulepin

                  huperzine A increases and dosulepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • doxepin

                  huperzine A increases and doxepin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • echothiophate iodide

                  echothiophate iodide and huperzine A both increase cholinergic effects/transmission. Use Caution/Monitor.

                • fesoterodine

                  huperzine A increases and fesoterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • flavoxate

                  huperzine A increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • galantamine

                  galantamine and huperzine A both increase cholinergic effects/transmission. Use Caution/Monitor.

                • glycopyrrolate

                  huperzine A increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • glycopyrrolate inhaled

                  huperzine A increases and glycopyrrolate inhaled decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • henbane

                  huperzine A increases and henbane decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • homatropine

                  huperzine A increases and homatropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • hyoscyamine

                  huperzine A increases and hyoscyamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • hyoscyamine spray

                  huperzine A increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

                • imipramine

                  huperzine A increases and imipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • incobotulinumtoxinA

                  huperzine A increases and incobotulinumtoxinA decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • ipratropium

                  huperzine A increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • lofepramine

                  huperzine A increases and lofepramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • maprotiline

                  huperzine A increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • meclizine

                  huperzine A increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • methscopolamine

                  huperzine A increases and methscopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • neostigmine

                  huperzine A and neostigmine both increase cholinergic effects/transmission. Use Caution/Monitor.

                • nortriptyline

                  huperzine A increases and nortriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • onabotulinumtoxinA

                  huperzine A increases and onabotulinumtoxinA decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • orphenadrine

                  huperzine A increases and orphenadrine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxybutynin

                  huperzine A increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxybutynin topical

                  huperzine A increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • oxybutynin transdermal

                  huperzine A increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pancuronium

                  huperzine A increases and pancuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • physostigmine

                  huperzine A and physostigmine both increase cholinergic effects/transmission. Use Caution/Monitor.

                • pilocarpine

                  huperzine A and pilocarpine both increase cholinergic effects/transmission. Use Caution/Monitor.

                • pilocarpine ophthalmic

                  huperzine A and pilocarpine ophthalmic both increase cholinergic effects/transmission. Use Caution/Monitor.

                • pralidoxime

                  huperzine A increases and pralidoxime decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • propantheline

                  huperzine A increases and propantheline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • protriptyline

                  huperzine A increases and protriptyline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • pyridostigmine

                  huperzine A and pyridostigmine both increase cholinergic effects/transmission. Use Caution/Monitor.

                • rapacuronium

                  huperzine A increases and rapacuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • rocuronium

                  huperzine A increases and rocuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • scopolamine

                  huperzine A increases and scopolamine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • solifenacin

                  huperzine A increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • succinylcholine

                  huperzine A and succinylcholine both increase cholinergic effects/transmission. Use Caution/Monitor.

                • tiotropium

                  huperzine A increases and tiotropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • tolterodine

                  huperzine A increases and tolterodine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • trazodone

                  huperzine A increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • trimipramine

                  huperzine A increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • trospium chloride

                  huperzine A increases and trospium chloride decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                • vecuronium

                  huperzine A increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                Minor (4)

                • donepezil

                  donepezil increases effects of huperzine A by pharmacodynamic synergism. Minor/Significance Unknown.

                • galantamine

                  galantamine increases effects of huperzine A by pharmacodynamic synergism. Minor/Significance Unknown.

                • pantothenic acid

                  pantothenic acid, huperzine A. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown.

                • procainamide

                  procainamide decreases effects of huperzine A by pharmacodynamic antagonism. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Gastrointestinal effects (eg, nausea, diarrhea)

                Sweating

                Blurred vision

                Fasciculations

                Dizziness

                See cholinergic syndrome

                Previous
                Next:

                Warnings

                Contraindications

                Seizure disorders, cardiac arrhythmias, asthma, IBS, IBD & malabsorption syndromes

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: avoid

                Lactation: avoid

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Absorption: readily from GI tract

                Distribution: wide, including brain

                Peak Plasma Time: 80 min

                Metabolism: some first pass metabolism in liver

                Excretion: N/A

                Mechanism of Action

                Cholinesterase inhibitor

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.